Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surface-modified LPD nanoparticles for tumor targeting.

Shyh-Dar Li1, Leaf Huang

  • 1Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

Annals of the New York Academy of Sciences
|December 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formulation and administration timing of lipid derivatized JAK-inhibitor and corticosteroid modulate saRNA-LNP inflammation and expression.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Incorporation of a polyamine into lipid nanoparticles increases the endosomal release and transfection of nucleic acids without toxicity.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Emerging vesicular nanosystems capable of effectively targeting hepatocytes.

Nanomedicine (London, England)·2025
Same author

Biodegradable polymers with tertiary amines enhance mRNA delivery of lipid nanoparticles via improved endosomal escape.

Biomaterials·2025
Same author

Imiquimod-Loaded Phospholipid-Free Small Unilamellar Vesicles Activate the Tumor Immune Microenvironment to Treat Liver Cancer and Liver Metastases.

Advanced healthcare materials·2025
Same author

Targeting tumor-associated microbiome: A new aspect of modulating tumor microenvironment for cancer therapy.

Advanced drug delivery reviews·2025
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

Surface-modified liposome-polycation-DNA (LPD) nanoparticles enhance siRNA delivery for cancer therapy. This targeted approach significantly boosts gene silencing and apoptosis in lung cancer cells, offering a promising new treatment strategy.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Cancer Research

Background:

  • siRNA (small interfering RNA) holds therapeutic potential for cancer but faces challenges in targeted delivery.
  • Liposome-polycation-DNA (LPD) complexes offer a platform for nucleic acid delivery.
  • Surface modification is crucial for improving the efficacy and targeting of LPD formulations.

Purpose of the Study:

  • To develop and evaluate a surface-modified, targeted LPD formulation for enhanced siRNA delivery in cancer therapy.
  • To assess the impact of surface modification and PEGylation on LPD delivery efficiency and gene-silencing effects.
  • To investigate the therapeutic potential of targeted LPD-siRNA in inducing apoptosis and chemosensitization in lung cancer models.

Main Methods:

  • Development of a surface-modified, PEGylated LPD formulation for siRNA encapsulation.

Related Experiment Videos

  • In vitro assessment of LPD delivery efficiency and gene-silencing effects in human lung cancer cells.
  • Evaluation of apoptosis induction and chemosensitization to cisplatin in cancer cells treated with targeted LPD-siRNA.
  • In vivo studies using a human lung cancer xenograft model (NCI-H460) to assess tumor localization and siRNA uptake.

    • Main Results:

    • Surface-modified, PEGylated LPD demonstrated a four-fold increase in siRNA delivery efficiency.
    • Gene-silencing effects were enhanced two- to three-fold compared to unmodified LPD.
    • Targeted LPD-siRNA induced 90% apoptosis in human lung cancer cells and sensitized them to cisplatin by four-fold.
    • Significant tumor localization of siRNA was observed in vivo, with tumors being the primary uptake site.

    Conclusions:

    • Surface-modified LPD is a potent and effective carrier for siRNA delivery in cancer therapy.
    • PEGylated LPD formulations enhance siRNA delivery, gene silencing, and therapeutic outcomes in lung cancer.
    • This targeted nanocarrier system shows significant promise for RNA interference-based tumor treatment strategies.